Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...
D. Boral Capital analyst Jesse Sobelson reiterated a Buy rating on the shares of MicroVision Inc (NASDAQ:MVIS) with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback